<DOC>
	<DOCNO>NCT01956734</DOCNO>
	<brief_summary>Phase I trial , unicentric , uncontrolled . Intratumoral injection intramural ( resected tumor cavity ) DNX2401 brain tissue follow two 28 - day cycle oral temozolomide ( TMZ ) schedule 7 day on/7 day evaluate safety combination . Completion two full cycle TMZ dependent upon tolerance toxicity . The rationale use virus chemotherapy begin lesson learn many clinical trial glioblastoma ( GBM ) great difficulty treat disease monotherapy limitation therapeutic virus . The best clinical result recent year achieve combination multiple therapeutic effort , include , maximum resection chemotherapy , immunotherapy target therapy . There strong preclinical data synergy DNX-2401 TMZ propose trial design . The dose-dense scheme TMZ like one use , develop aim saturate o6-methylguanine-DNA-methyltransferase ( MGMT ) . The publish result date show reasonable toxicity albeit modest efficacy ' scheme phase III trial . In addition , autophagy trigger TMZ could help viral replication tumor cell 11 . The last argument favor virus + TMZ combination prove efficacy kill GBM tumor stem cell . In vitro animal model show combination much effective treatment alone GBM stem cell tumor derive .</brief_summary>
	<brief_title>Virus DNX2401 Temozolomide Recurrent Glioblastoma</brief_title>
	<detailed_description>DNX2401 inject stereotactic biopsy reveals intraoperative pathology confirm presence recurrent glioblastoma . The injection either intratumoral intramural injection throughout post-resection cavity .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Inclusion criterion : Patients willing able give inform consent willing comply protocol procedure . Patient must , investigator opinion , able comply protocol procedure . Age 1875 year . Negative pregnant test case fertile woman . Patient diagnose GBM first recurrence radiotherapy TMZ . Must complete least radiotherapy one TMZ cycle afterwards . Intraoperative histological verification recurrence need confirm inclusion . Karnofsky Performance Status ≥ 70 inclusion Lesion consider investigator resectable accessible stereotactic biopsy . Lesion location allow injection without entrance virus ventricular system . Last TMZ cycle must finish least 4 week entry study . Must adequate renal , bone marrow liver function . Exclusion criterion : Severe infection intercurrent medical condition include , limited , severe renal , hepatic , heart bone marrow failure , , investigator´s criterion , allow inclusion . Participation another clinical trial previous 30 day . Previous hypersensitivity temozolomide associated component . Previous serious toxicity temozolomide . Subjects immunodeficiency , autoimmune condition active hepatitis . Any medical psychological condition might interfere subject 's ability participate give informed consent . Tumor multiple location , unless lesion consider resectable , lesion except one resect , last one inject ; diffuse subependymal spread location would need injection ventricle . Current diagnosis cancer except situ cervical cancer , basal squamous cell carcinoma skin . Patients history another cancer remain eligible cancer free least three year . Pregnant breastfeeding female exclude , due risk fetal development recombinant virus contain gene relate cellular growth differentiation . Severe bone marrow hypoplasia . Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) &gt; 3 time normal laboratory level .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>glioblastoma</keyword>
	<keyword>first recurrence</keyword>
	<keyword>temozolomide</keyword>
</DOC>